Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Neurex
Patients are randomized to receive SNX-111 or placebo (AS PER AMENDMENT 1/22/98: with randomization weighted 2:1 in favor of SNX-111) via external pump and an intrathecal catheter (thin tube inserted into the spinal canal). (AS PER AMENDMENT 1/22/98: the dose is increased every 24 hours, in the absence of onset of analgesia or adverse events. After 2-5 days, patients who respond to their medication continue treatment at home for 5-8 days. Patients who do not respond will be switched to the other regimen (i.e., placebo to SNX-111, or SNX-111 to placebo). After 10 days, responding patients are unblinded and asked to enroll in the long-term, open-label extension protocol. Patients remain on a fixed dose at the therapeutic level found in the previous study. The dose may be increased or decreased at the discretion of the investigator. Patients may continue therapy on a long-term basis until the drug is approved.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Allowed:
Rescue analgesia.
Patients must have:
Chronic pain related to AIDS or cancer.
Unsatisfactory response to prior opioid therapy.
Life expectancy \> 3 months (or 1 month if an infusion pump is in place).
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Signs of sepsis or inadequately treated infection.
Patients with the following prior conditions are excluded:
History of heart disease, heart failure, or asthma.